| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 71288-0117-28 | 71288-0117 | Gemcitabine hydrochloride | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 11, 2020 | In Use | |
| 00378-4791-06 | 00378-4791 | Fluorouracil | Fluorouracil | 5.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Sep 19, 2013 | In Use | |
| 63323-0763-17 | 63323-0763 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 15, 2014 | Dec 31, 2016 | In Use |
| 70121-1644-01 | 70121-1644 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 1, 2019 | In Use | |
| 16729-0295-34 | 16729-0295 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | INTRACAVERNOUS, Intravenous | Sep 19, 2017 | In Use | |
| 31722-0416-31 | 31722-0416 | TEMOZOLOMIDE | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 23, 2024 | In Use | |
| 60429-0265-01 | 60429-0265 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Oct 26, 2012 | Dec 31, 2024 | No Longer Used |
| 59923-0725-30 | 59923-0725 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 1, 2020 | In Use | |
| 00069-0231-01 | 00069-0231 | Lorlatinib | Lorbrena | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Nov 19, 2018 | In Use | |
| 70518-1398-02 | 70518-1398 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct 18, 2018 | In Use | |
| 70771-1395-03 | 70771-1395 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 55150-0393-01 | 55150-0393 | AZACITIDINE | AZACITIDINE | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan 3, 2023 | In Use | |
| 83831-0140-02 | 83831-0140 | CARBOplatin | KYXATA | 20.0 mg/2mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug 11, 2025 | In Use | |
| 83634-0204-02 | 83634-0204 | Thiotepa | Thiotepa | 15.0 mg/1.5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | Oct 1, 2025 | In Use | |
| 42291-0939-12 | 42291-0939 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms | Oral | Apr 23, 2024 | In Use | |
| 50090-2345-09 | 50090-2345 | Methotrexate, Methotrexate sodium | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Apr 8, 2016 | In Use | |
| 61703-0305-38 | 61703-0305 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Jun 4, 1990 | In Use | |
| 54868-5218-01 | 54868-5218 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Aug 17, 1999 | In Use | |
| 59923-0709-05 | 59923-0709 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan 25, 2019 | In Use | |
| 75834-0145-05 | 75834-0145 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 7, 2021 | In Use | |
| 16729-0267-64 | 16729-0267 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 2, 2013 | In Use | |
| 61703-0344-18 | 61703-0344 | Fludarabine Phosphate | Fludarabine Phosphate | 50.0 mg/2mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Sep 25, 2008 | Sep 30, 2021 | No Longer Used |
| 70771-1902-06 | 70771-1902 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 16729-0332-05 | 16729-0332 | OXALIPLATIN | OXALIPLATIN | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 17, 2018 | In Use | |
| 60505-3801-02 | 60505-3801 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 23, 2025 | In Use |
Found 12159 results — Export these results
Home